Clinical Trial

TRIAD - Tracking Risk in Integrated Alzheimer's Diagnostics.

Study acronym: TRIAD
Recruiting
View on ClinicalTrials.gov →
Summary
The study is based on the hypothesis that the integration of biological, psychological, and social factors, according to the biopsychosocial paradigm, allows for more accurate identification of the different stages of the Alzheimer's continuum (AD), facilitating early diagnosis and effective management. It is also hypothesized that the experience of the caregiver is a key element, capable of influencing the patient's experience and clinical course, representing a potential early indicator of risk. Primary objectives are (PO.1) Jointly analyze biological, psychological, and social factors at different stages of the AD continuum to construct multidimensional clinical profiles and integrated risk models. (PO.2) Examine the influence of psychological and social variables on the quality of life of patients and caregivers at different stages of the disease. (PO.3) Investigate the relationship between caregiver psychological well-being and patient cognitive functioning, exploring potentially bidirectional relationships. Secondary objectives are (SO.1) Compare biomarkers and neuropsychological performance at different stages of the AD clinical continuum. (SO.2) Evaluate the diagnostic effectiveness of blood and neuroimaging biomarkers in discriminating the severity of cognitive impairment. (SO.3) Explore stress and coping strategies adopted by caregivers, in relation to the stage of the disease and the quality of the dyadic relationship. (So.4) Integrate quantitative and qualitative data to understand the emotional experience of the caregiver throughout the entire disease continuum.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-02.
Trial Details
NCT Number NCT07399418
Lead Sponsor Istituti Clinici Scientifici Maugeri SpA
Collaborators: Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions Cognitive Decline
Enrollment 80 participants
Start Date 2025-09-01
Primary Completion 2027-07-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-17